GENFIT-ADR (GNFT) Stock Price, Quote, News and Overview
NASDAQ:GNFT - Nasdaq - US3722791098 - ADR - Currency: USD
GNFT Quote, Performance and Key Statistics
NASDAQ:GNFT (2/21/2025, 8:24:09 PM)
3.83
-0.09 (-2.3%)
The current stock price of GNFT is 3.83 USD. In the past month the price increased by 3.51%. In the past year, price increased by 4.64%.
GNFT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GNFT
Company Profile
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 169 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Company Info
GENFIT-ADR
Parc Eurasante 885 avenue Eugene Avinee
LOOS HAUTS-DE-FRANCE 59120 FR
CEO: Pascal Prigent
Employees: 169
Company Website: https://www.genfit.fr/
Investor Relations: http://www.genfit.com/investors/financial-informations/
Phone: 33320164000
GENFIT-ADR / GNFT FAQ
What is the stock price of GENFIT-ADR today?
The current stock price of GNFT is 3.83 USD. The price decreased by -2.3% in the last trading session.
What is the ticker symbol for GENFIT-ADR stock?
The exchange symbol of GENFIT-ADR is GNFT and it is listed on the Nasdaq exchange.
On which exchange is GNFT stock listed?
GNFT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GENFIT-ADR stock?
13 analysts have analysed GNFT and the average price target is 10.22 USD. This implies a price increase of 166.91% is expected in the next year compared to the current price of 3.83. Check the GENFIT-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GENFIT-ADR worth?
GENFIT-ADR (GNFT) has a market capitalization of 190.97M USD. This makes GNFT a Micro Cap stock.
How many employees does GENFIT-ADR have?
GENFIT-ADR (GNFT) currently has 169 employees.
What are the support and resistance levels for GENFIT-ADR (GNFT) stock?
GENFIT-ADR (GNFT) has a support level at 3.5 and a resistance level at 4.07. Check the full technical report for a detailed analysis of GNFT support and resistance levels.
Is GENFIT-ADR (GNFT) expected to grow?
The Revenue of GENFIT-ADR (GNFT) is expected to grow by 48.34% in the next year. Check the estimates tab for more information on the GNFT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GENFIT-ADR (GNFT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GNFT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GNFT, evaluating the profitability, health, valuation and growth aspects
- GENFIT-ADR (GNFT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GENFIT-ADR (GNFT) Sales and EPS estimates to see what analysts future expectations are.
- GENFIT-ADR (GNFT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GENFIT-ADR (GNFT) Insider and Institutional Ownership to learn about the owners and their transactions.
- GENFIT-ADR (GNFT) Stock Chart to make your own analysis
- GENFIT-ADR (GNFT) Latest news and press-releases to stay up to date.
Does GENFIT-ADR (GNFT) stock pay dividends?
GNFT does not pay a dividend.
When does GENFIT-ADR (GNFT) report earnings?
GENFIT-ADR (GNFT) will report earnings on 2025-05-22.
What is the Price/Earnings (PE) ratio of GENFIT-ADR (GNFT)?
The PE ratio for GENFIT-ADR (GNFT) is 8.15. This is based on the reported non-GAAP earnings per share of 0.47 and the current share price of 3.83 USD. Check the full fundamental report for a full analysis of the valuation metrics for GNFT.
What is the Short Interest ratio of GENFIT-ADR (GNFT) stock?
The outstanding short interest for GENFIT-ADR (GNFT) is 0.23% of its float. Check the ownership tab for more information on the GNFT short interest.
GNFT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GNFT. When comparing the yearly performance of all stocks, GNFT is a bad performer in the overall market: 65.07% of all stocks are doing better.
GNFT Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GNFT. GNFT has a medium profitability rating, but doesn't score so well on its financial health evaluation.
GNFT Financial Highlights
Over the last trailing twelve months GNFT reported a non-GAAP Earnings per Share(EPS) of 0.47. The EPS increased by 153.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 26.51% | ||
| ROA | 11.43% | ||
| ROE | 22.87% | ||
| Debt/Equity | 0.61 |
GNFT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 91% to GNFT. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 389.04% and a revenue growth 48.34% for GNFT